Journal article
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation
Cancer letters, Vol.311(2), pp.219-229
08/06/2011
DOI: 10.1016/j.canlet.2011.07.023
PMCID: PMC3183362
PMID: 21872389
Abstract
The goal of this study is to determine whether treatment with methylselenocysteine (MSC) results in differential uptake of irinotecan and its active metabolite (SN-38) between tumors of head and neck squamous cell carcinomas and normal tissue. The in vivo synergy between MSC and irinotecan is influenced by treatment schedule and associated with enhancement of tumor vessel maturation, intra-tumor concentration of SN-38 and apoptotic death of tumor cells. Normal tissue drug concentrations of were not impacted by selenium treatment. The finding is of clinical relevance for enabling the delivery of higher doses of irinotecan to reverse tumor resistance, recurrence and ultimately enhancing cure rates.
Details
- Title: Subtitle
- Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation
- Creators
- Rami G. Azrak - Roswell Park Cancer InstituteShousong Cao - Roswell Park Cancer InstituteFarukh A. Durrani - Roswell Park Cancer InstituteKarloy Toth - Roswell Park Cancer InstituteArup Bhattacharya - Roswell Park Cancer InstituteYoucef M. Rustum - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Cancer letters, Vol.311(2), pp.219-229
- DOI
- 10.1016/j.canlet.2011.07.023
- PMID
- 21872389
- PMCID
- PMC3183362
- ISSN
- 0304-3835
- eISSN
- 1872-7980
- Grant note
- P30 CA016056-35 || CA / National Cancer Institute : NCI
- Language
- English
- Date published
- 08/06/2011
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363164202771
Metrics
19 Record Views